Brexucabtagene autoleucel

Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy used to treat mantle cell lymphoma and acute lymphoblastic leukemia. It belongs to the chimeric antigen receptor T cell, or CAR-T, therapy category and was the first cell-based gene therapy approved by the FDA for mantle cell lymphoma. A patient's own T cells are collected and genetically modified to carry a new gene that helps the cells target and destroy lymphoma or leukemia cells, and the engineered cells are then infused back into the patient. It received FDA approval for relapsed or refractory mantle cell lymphoma in July 2020 and European Union approval in December 2020, then FDA approval for relapsed or refractory B-cell precursor acute lymphoblastic leukemia in October 2021 and European Union approval in December 2021.